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Our goal is to study the efficacy and safety of MTX in juve-
nile localized scleroderma (JLS).
Retrospective study of 59 chlidren with JLS from 3 to 17 y
(M = 10.3) treated with MTX was performed. Group 1 (n
= 18) – received prednisone 0.5 mg\kg for 6 weeks, taped
to 0.1 mg\kg for 12 months + MTX 10 mg\body sq. weekly
for 13.7 mo. Group 2 (n = 41) -MTX the same doses and
duration. The efficacy was measured in 6 & 12 months
using skin score, activity and sclerosis indexes (IA, IS) (1 –
3 points) of skin damage, the safety by clinical & labora-
tory methods. Group 1 patients had spread linear skin
involvement (hemitype), with skin score significantly
higher (p < 0.01) than in group 2, where children had
mostly local linear skin damage. Previously 9 pts from
Group 1, 31 pts from Group 2 received penicillamine
(PA) with no effect.
MTX therapy was effective in 73% of children unsuccess-
fully treated with PA & in 98% of patients received MTX as
the first medication. Effect of therapy was significantly
better in pts with disease duration less than 6 mo. In
Group 1 significant improvement (p < 0.01) in skin score,
IA, IS had been already achieved in 6 months of treat-
ment, in Group 2 only in 12 mo. MTX was effective in
children with linear skin, periarticular contractures. Nau-
sea was the main adverse effect, in 17% of pts, with no
correlation with genetic polymorfisms of methylenetet-
rahydrofolate reductase.
MTX is effective and safe in linear JLS.
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